We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HSC

News List

Kite and Appia Bio to develop allogeneic cell therapies for blood cancer pharmaceutical-technology
August 09, 2021
Gilead unit Kite and Appia Bio have signed a partnership and licence agreement to research and develop off-the-shelf allogeneic cell treatments from hematopoietic stem cells (HSCs) for haematological cancers.
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer americanpharmaceuticalreview
August 06, 2021
Kite, a Gilead Company, and Appia Bio, Inc. announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies.
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities firstwordpharma
June 15, 2021
Cellectis S.A., a clinical-stage biotechnological company employing its core proprietary technologies to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor (CAR) T-cells in the field of immuno-oncology